Anul IX nr. 1

APÃRAREA NBC 15/2008CBRN medicalSIGURANÞA CERCETÃRII CLINICEÎN PROTECÞIA MEDICALÃ, NUCLEARÃ, CHIMICÃ ªI BIOLOGICÃColonel (r) dr.bioch.farm. Constantin STANColonel dr.ing.Ion SAVUProf.univ.dr. Aurelia Nicoleta CRISTEAProf.univ.dr. Natalia ROªOIUThe in vivo radiobiological internal decontamination of uranium isotopes, radionuclides and heavy metalsrepresented a new scientific discovery for the NBC Medical Protection domain.The fundamental research for in vivo internal decontamination of uranium is based on verified and evidentresults, obtained in scientific experiments on standard animals, where uranium (235U) was used as contaminantagent within competition researches in the area of the Nuclear Medicine.The experimental research sustains and describes reference data and results from the research meant to obtainnew and efficient biologically active products for radiobiological and chemical decontamination of uranium, radionuclidesand noxious chemicals. The originally patented compound is named Stanosimagne PP 6-006. The non-clinical(pre-clinical) pharmacology research was developed and performed on 635 standard animals (rats, mice, rabbits andguinea pigs) in concordance with the current regulations and settlements of the Romanian National Drug Agency.The product is not toxic; the lethal dose (LD1=0) has not been reached at a dose of 1.3g powder/kg-body,approximately 100g-powder/70Kg, or 700capsules/70Kg. The medicine is integrated in pharmaceutical products withouttoxicity or contrary reaction and it is indicated in the efficient treatment for biological decontamination ofUranium isotopes, radionuclides and heavy metals, respectively in the Mercury and Lead intoxication.The applicative pharmacology researches, in several pilot clinical studies on human cases of accidental or provokedinternal contamination with heavy metals and in radiological or orthopedic professional contamination, hasbeen carried out by Col.(r)dr.bioch.pharm. Constantin Stan, along with medical, pharmaceutical and biochemicaldidactic specialists from the Laboratories Departments of Pharmacology, Phytochemistry, Biochemistry, OrganicChemistry and Pharmaceutical Technique of the University of Medicine and Pharmacy "Carol Davila", Bucharest.IntroducereÎn lucrarea de faþã se prezintã datele cercetãrilorde înaltã competiþie, în domeniul Medicinei Nucleare,efectuate în scopul obþinerii unor produºi biologic activieficienþi în decontaminarea radiobiologicã ºi chimicã auraniului, radionuclizilor ºi a altor noxe chimice.În stadiul actual, medicaþia bolii de iradiere seadreseazã exclusiv tratamentului simptomelor ºi leziunilordeterminate la nivelul diferitelor þesuturi ºi organe(1-6). Referitor la decontaminarea radiobiologicã, nuexistã încã o medicaþie eficientã ºi nici profilacticã.Pe plan internaþional, conceperea ºi aplicarea detratamente cu efect decorporator asupra organismelorcontaminate accidental sau experimental, au constituit opermanentã preocupare ºtiinþificã privind decontaminarearadiobiologicã in vivo sau in vitro a izotopilor uraniuluiºi a unor metale grele [7-11]. Experimentele nonclinice(preclinice), cu chelatorii molecular-sintetici Me-3,2-HOPO [7], 3,4,3-LIHOPO [8] ºi Ethane-1-Hydroxy-1,1-Bis-phosphonate (EHBP) [8], ºi 4,4,4-LIHOPO, comparativcu DTPA [10], dupã contaminarea ºobolanilor cuforme solubile de 203 Pb, 238 Pu ºi uraniu ( 233 U), datoritã toxicitãþiiacute, nu au dezvoltat rezultate aplicabile clinic.În cercetarea fundamentalã privind decontaminarearadiobiologicã in vivo a uraniului cu produsulfarmaceutic STANOSIMAGNE PP 6-006 capsule ºiunguent [12-17] s-au obþinut rezultate certe ºi evidenteîn experimentele ºtiinþifice pe animale standard, în care afost utilizat uraniu (izotopul 235 U) ca agent contaminant.Descoperirea ºtiinþificã se bazeazã pe faptul cãmedicamentul STANOSIMAGNE îndeplineºte scopul propuscu un Timp biologic de înjumãtãþire Tb 1/2 =8zile, estebine tolerat ºi se încadreazã în produsele farmaceuticefãrã toxicitate sau reacþii adverse, întrucât în experimentelenon-clinice pentru determinarea toxicitãþii acuteºi cronice, nu s-a atins doza letalã 1%, rezultatul fiindDL1=0%, la o dozã maximã administratã de 1,3g-pulbere/Kg-corp.Produsul farmaceutic STANOSIMAGNE ºi aplicareatratamentului destinat protecþiei medicale radiobiologicea personalului, se adreseazã în principal sistemuluiendocrin, glandelor endocrine, pentru propria eliberarede agentul toxic. Prin recuperarea deficitelor principalelorminerale ºi oligoelemente provocate de iradiere, în cir-99